Navigation Links
NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Date:4/22/2009

://www.novabaypharma.com" target="_new">www.novabaypharma.com.

Cautionary Information Regarding Forward-Looking Statements

The statements in this press release of NovaBay's expectations regarding the timing of commencement of NVC-422 clinical trials, the benefits to NovaBay from the agreements with Professors Gottardi and Nagl, and the potential efficacy of NovaBay's Aganocide compounds, are forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the risk that results obtained in animal models may not be obtained in humans, and the risk of unexpected delays in the regulatory process may delay the commencement or completion of clinical trials. Other risks relating to NovaBay and its Aganocide compounds , including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Annual Report on Form 10-K, under the caption "Risk Factors" in Item 1A of Part I of that report, which was filed with the Securities and Exchange Commission on March 31, 2009.

    For more information

    NovaBay Pharmaceuticals, Inc.
    Chief Financial Officer:
    Tom Paulson, 510-899-8809
    tpaulson@novabaypharma.com

    Invigorate Communications
    Investor Relations:
    Gregory Gin, 908-376-7737
    ggin@invigoratepr.com

    Media Relations:
    Mariesa Kemble, 608-850-4745
    mkemble@invigoratepr.com


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... device R&D outsourcing company with operations in China ... today announced that it will release financial results for the ... closes on Wednesday, August 13, 2014 (which will be Thursday ... be available on the investor relations section of the Company,s ...
(Date:7/22/2014)... 22, 2014  Pressure BioSciences, Inc. (OTCQB: ... Genomics ("Parabase"), (together "the companies"), today announced ... and development agreement (the "collaboration"). Under the ... a front-end, sample preparation method for Parabase,s ... testing process. The sample preparation method will ...
(Date:7/22/2014)... New York , July 22, ... Neue Partnerschaft für umfassenden Schutz von ... in Österreich    Equashield ... von geschlossenen Transfersystemen (Closed System Transfer Devices, CSTDs) für ... , einen Vertriebshändler und Hersteller von ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
(Date:7/22/2014)... July 22, 2014) The American Society of Hematology ... University School of Medicine, and Robert P. Hebbel, MD, ... 2014 Ernest Beutler Lecture and Prize for their significant ... , The Ernest Beutler Lecture, named for the late ... physician-scientist for more than 50 years, is a two-part ...
(Date:7/22/2014)... 22, 2014) -- The American Society of Hematology (ASH) ... H. Coulter Award for Lifetime Achievement in Hematology, to ... Island Jewish (LIJ) School of Medicine for his 50-year ... education and mentoring, and exceptional patient care. , ... Hematology is bestowed on an individual who has been ...
(Date:7/22/2014)... -- New guidelines on cholesterol treatment and cardiovascular risk ... risk of dying from atherosclerotic cardiovascular disease or of ... with a similar risk profile (based on age, smoking ... of this finding for when and how aggressively to ... Journal of Men,s Health , a peer-reviewed publication ...
(Date:7/22/2014)... July 22, 2014 The Entertainment Industries ... providing resources, educational tools and recognition activities for thousands ... of prevention, treatment and recovery. On July 24, 2014, ... spotlight some of these resources with a special mention ... helpline and treatment website at the end of the ...
(Date:7/22/2014)... July 22, 2014 (HealthDay News) --,High school lacrosse players ... as well as games, a new study finds. ... more than 22 percent are concussions, researchers report. They ... happening could lead to better ways to protect student ... girls, lacrosse underscores the need to learn more about ...
Breaking Medicine News(10 mins):Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 3
... This release is available in German . ... operation requires a wide variety of surgical instruments, from simple ... as cerclage wire passers, which surgeons employ to repair long, ... way as to half encircle the broken bone, and incorporate ...
... may be exaggerated, according to scientists from the Swedish medical ... Journal of Physiology , shows that free radicals act as ... correct force. Free radicals are molecules that react readily ... negative effects on health in certain circumstances, through the damage ...
... Blindly copying what your parents did no matter how ... for the long-term success of your genes, according to research ... of the study, published in Ecology Letters , show ... migration of many animals to breed at the place they ...
... Feb. 28 (HealthDay News) -- Cancer patients undergoing chemotherapy ... and malnutrition by taking fish oil supplements that contain ... is based on a small study involving just 40 ... simple, noninvasive intervention might go a long way towards ...
... Feb. 28, 2011 A gel developed to protect against ... used in the rectum, according to an early-phase study presented ... (CROI). The results, based on rectal tissue biopsies sampled from ... one week, provide the first-ever evidence that tenofovir gel could ...
... supplementing the diet with fish oil may prevent muscle ... who undergo chemotherapy. Published early online in Cancer ... the study indicates that fish oil may help combat ... lose muscle mass and become malnourished, leading to fatigue, ...
Cached Medicine News:Health News:Surgical instruments with electronic serial numbers 2Health News:Free radicals may be good for you 2Health News:'Stupid strategies' could be best for the genes 2Health News:Fish Oil Seems to Help Cancer Patients Preserve Muscle 2Health News:Fish Oil Seems to Help Cancer Patients Preserve Muscle 3Health News:Tenofovir gel provides high level of protection against HIV in rectal tissue 2Health News:Tenofovir gel provides high level of protection against HIV in rectal tissue 3Health News:Tenofovir gel provides high level of protection against HIV in rectal tissue 4Health News:Fish oil fights weight loss due to chemotherapy 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: